Jaguar Health (JAGX) Cash from Financing Activities (2014 - 2026)

Jaguar Health (JAGX) has 13 years of Cash from Financing Activities data on file, last reported at -$6.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$6.6 million, down 233.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.1 million (down 49.42% YoY), and the FY2025 annual result was $23.7 million, down 24.14% from the prior year.
• Cash from Financing Activities fell to -$6.6 million in Q1 2026 per JAGX's latest filing, from $9.8 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $18.8 million in Q1 2023 and troughed at -$6.6 million in Q1 2026.
• A 5-year average of $6.2 million and a median of $5.0 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities soared 2620.38% in 2022, then tumbled 233.21% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $1.6 million in 2022, then soared by 550.18% to $10.6 million in 2023, then tumbled by 73.43% to $2.8 million in 2024, then soared by 245.94% to $9.8 million in 2025, then plunged by 167.57% to -$6.6 million in 2026.
• Business Quant data shows JAGX's Cash from Financing Activities at -$6.6 million in Q1 2026, $9.8 million in Q4 2025, and $6.3 million in Q3 2025.